(MPLT) MapLight Therapeutics - Overview
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.328m USD | Total Return: 56.8% in 12m
Avg Turnover: 6.60M
Warnings
Altman Z'' -15.00 < 1.0 - financial distress zone
Choppy
Tailwinds
Leader
MapLight Therapeutics, Inc. (MPLT) is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system (CNS) disorders. Its primary pipeline candidate, ML-007C-MA, targets schizophrenia and Alzheimers disease psychosis through a muscarinic agonist mechanism. The company’s broader portfolio includes treatments for autism spectrum disorder, Parkinson’s disease, and neuropsychiatric conditions, supported by a proprietary platform that maps neural circuits linked to specific diseases.
The biotechnology sector often requires significant capital investment and long development timelines, as clinical-stage firms must navigate rigorous multi-phase FDA approval processes before generating commercial revenue. MapLight’s business model centers on the high-risk, high-reward nature of neuroscience, where successful drug candidates address substantial unmet needs in complex chronic conditions. Investors may evaluate more comprehensive financial metrics and pipeline milestones on ValueRay to better understand the companys valuation.
Formerly known as Alvarado Therapeutics, the firm rebranded in 2019 and maintains its headquarters in Redwood City, California. Its research strategy emphasizes G-protein-coupled receptors and neural circuit modulation to treat behavioral symptoms such as hyperactivity, impulsivity, and social communication deficits.
- Clinical trial data for ML-007C-MA determines valuation in schizophrenia and Alzheimer’s markets
- FDA regulatory milestones for muscarinic agonist candidates dictate long-term commercial viability
- R&D expenditure and cash runway sustainability influence near-term equity financing needs
- Expansion of neural circuit platform validates pipeline diversification and strategic partnership potential
- Competition from established CNS therapies impacts future market share and pricing power
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.39 > 0.02 and ΔFCF/TA 37.14 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.39 > 3% & CFO -163.8m > Net Income -199.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.91 > 1.5 & < 3 |
| Outstanding Shares: last quarter (45.3m) vs 12m ago 9.29% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM) |
| A: 0.75 (Total Current Assets 327.2m - Total Current Liabilities 14.3m) / Total Assets 418.8m |
| B: -1.01 (Retained Earnings -421.2m / Total Assets 418.8m) |
| C: -0.79 (EBIT TTM -209.2m / Avg Total Assets 265.2m) |
| D: -22.27 (Book Value of Equity -422.1m / Total Liabilities 19.0m) |
| Altman-Z'' = -27.06 = D |
As of May 24, 2026, the stock is trading at USD 29.28 with a total of 157,741 shares traded.
Over the past week, the price has changed by +0.07%,
over one month by -10.52%,
over three months by +57.10% and
over the past year by +56.76%.
MapLight Therapeutics has no consensus analysts rating.
Revenue TTM = 0.0 USD
EBIT TTM = -209.2m USD
EBITDA TTM = -208.7m USD
Long Term Debt = 4.67m USD (estimated: total debt 5.59m - short term 920k)
Short Term Debt = 920k USD (from shortTermDebt, last quarter)
Debt = 5.59m USD (from shortLongTermDebtTotal, last quarter) (leases 5.59m already included)
Net Debt = -304.5m USD (calculated: Debt 5.59m - CCE 310.1m)
Enterprise Value = 1.02b USD (1.33b + Debt 5.59m - CCE 310.1m)
Interest Coverage Ratio = unknown (Ebit TTM -209.2m / Interest Expense TTM 0.0)
EV/FCF = -6.23x (Enterprise Value 1.02b / FCF TTM -164.3m)
FCF Yield = -16.05% (FCF TTM -164.3m / Enterprise Value 1.02b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 574k) / Revenue TTM)
Tobins Q-Ratio = 2.44 (Enterprise Value 1.02b / Total Assets 418.8m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 5.59m)
Taxrate = 21.0% (US default 21%)
NOPAT = -165.3m (EBIT -209.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 22.91 (Total Current Assets 327.2m / Total Current Liabilities 14.3m)
Debt / Equity = 0.01 (Debt 5.59m / totalStockholderEquity, last quarter 399.8m)
Debt / EBITDA = 1.46 (negative EBITDA) (Net Debt -304.5m / EBITDA -208.7m)
Debt / FCF = 1.85 (negative FCF - burning cash) (Net Debt -304.5m / FCF TTM -164.3m)
Total Stockholder Equity = 288.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -75.23% (Net Income -199.5m / Total Assets 418.8m)
RoE = -28.09% (Net Income TTM -199.5m / Total Stockholder Equity 710.1m)
RoCE = -29.27% (EBIT -209.2m / Capital Employed (Equity 710.1m + L.T.Debt 4.67m))
RoIC = -173.4% (out of range, set to none) (NOPAT -165.3m / Invested Capital 95.3m)
WACC = 11.06% (E(1.33b)/V(1.33b) * Re(11.11%) + D(5.59m)/V(1.33b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.11% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 61.46 | Cagr: 4.03%
[DCF] Fair Price = unknown (Cash Flow -164.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.40 | Chg30d=-17.70% | Revisions=N/A | Analysts=3
EPS next Quarter (2026-09-30): EPS=-1.34 | Chg30d=-14.21% | Revisions=N/A | Analysts=3
EPS current Year (2026-12-31): EPS=-5.27 | Chg30d=-14.31% | Revisions=N/A | GrowthEPS=+71.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-4.32 | Chg30d=-15.54% | Revisions=N/A | GrowthEPS=+18.1% | GrowthRev=+0.0%